<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3D352D44-EA95-45F1-AF90-FC7C18532C3D"><gtr:id>3D352D44-EA95-45F1-AF90-FC7C18532C3D</gtr:id><gtr:name>DNAVEC Corporation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C008EA20-84DD-4EEC-9F16-8FCA7C86311C"><gtr:id>C008EA20-84DD-4EEC-9F16-8FCA7C86311C</gtr:id><gtr:name>Imperial Innovations</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>RDM Clinical Laboratory Sciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3D352D44-EA95-45F1-AF90-FC7C18532C3D"><gtr:id>3D352D44-EA95-45F1-AF90-FC7C18532C3D</gtr:id><gtr:name>DNAVEC Corporation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C008EA20-84DD-4EEC-9F16-8FCA7C86311C"><gtr:id>C008EA20-84DD-4EEC-9F16-8FCA7C86311C</gtr:id><gtr:name>Imperial Innovations</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/34D3D542-EE34-47C2-B114-637F9B78F83C"><gtr:id>34D3D542-EE34-47C2-B114-637F9B78F83C</gtr:id><gtr:firstName>Eric</gtr:firstName><gtr:surname>Alton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9EA22A12-766E-4498-9358-3DD7660C4102"><gtr:id>9EA22A12-766E-4498-9358-3DD7660C4102</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Hyde</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BFBA507F-9D7D-4387-9C45-5407EC424062"><gtr:id>BFBA507F-9D7D-4387-9C45-5407EC424062</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Alastair</gtr:otherNames><gtr:surname>Innes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C03EFF95-9B7E-443D-9B7D-BD9AFDCDDBA5"><gtr:id>C03EFF95-9B7E-443D-9B7D-BD9AFDCDDBA5</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Pringle</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1BDFAAA7-0D7C-406F-A660-F243D1D333C9"><gtr:id>1BDFAAA7-0D7C-406F-A660-F243D1D333C9</gtr:id><gtr:firstName>Deborah</gtr:firstName><gtr:otherNames>Rebecca</gtr:otherNames><gtr:surname>Gill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5BA0D8E8-6B77-4743-804D-FC38B7EB6222"><gtr:id>5BA0D8E8-6B77-4743-804D-FC38B7EB6222</gtr:id><gtr:firstName>Laura</gtr:firstName><gtr:surname>Hyndman</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC993158-4A74-40D2-B76F-AB1ABF790168"><gtr:id>EC993158-4A74-40D2-B76F-AB1ABF790168</gtr:id><gtr:firstName>Mary</gtr:firstName><gtr:surname>Connolly</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/056E5D16-02D0-400D-B2C7-DD8B3D03E3BF"><gtr:id>056E5D16-02D0-400D-B2C7-DD8B3D03E3BF</gtr:id><gtr:firstName>Lee</gtr:firstName><gtr:otherNames>Adrian</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C45BFBE5-31C2-495A-8E88-9851467BB8EB"><gtr:id>C45BFBE5-31C2-495A-8E88-9851467BB8EB</gtr:id><gtr:firstName>June</gtr:firstName><gtr:surname>Brand</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1499F3BD-F827-4C0C-95A7-03B5292D5106"><gtr:id>1499F3BD-F827-4C0C-95A7-03B5292D5106</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Porteous</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C529D287-3497-4A57-B4A5-64A4B0FDCBFD"><gtr:id>C529D287-3497-4A57-B4A5-64A4B0FDCBFD</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ABB1F624-69D8-45AA-B21A-31821EAE8352"><gtr:id>ABB1F624-69D8-45AA-B21A-31821EAE8352</gtr:id><gtr:firstName>Uta</gtr:firstName><gtr:surname>Griesenbach</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/76727B4F-1FBE-4E2E-A9FA-BD0826243E61"><gtr:id>76727B4F-1FBE-4E2E-A9FA-BD0826243E61</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Boyd</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ014699%2F1"><gtr:id>0C4815C6-CC5C-4DB6-AF77-1CE07662BD90</gtr:id><gtr:title>Development of a novel, potent, safe, long-lasting lentivirus-based gene therapy for cystic fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J014699/1</gtr:grantReference><gtr:abstractText>Cystic Fibrosis (CF) is a common genetic disease that affects over 8000 people in the UK. It is the result of a mutation in a single gene called CFTR that causes the build up of thick sticky mucus in the lungs. Eventually the lungs become repeatedly infected and inflamed, leading to lung failure and premature death. All current therapies are aimed at coping with the symptoms; there is no cure. In 2001, three research groups in the UK formed the CF Gene Therapy Consortium to develop a new kind of treatment based on introducing new (healthy) copies of the CFTR gene into the lungs of people with CF. Many advances have been made, and we have learned a great deal about the obstacles to this approach, but we are not yet in a position to offer an effective gene therapy for CF lung disease. The aim of this research application is to use a new kind of gene therapy based on a virus called lentivirus, which we think has the potential to be more efficient at delivering the gene into the lungs and to provide an effective treatment for CF lung disease. In order to make the lentivirus carrying the CF gene as effective as possible, it is wrapped up in two new coat proteins called F and HN, a process known as 'pseudotyping'. We have shown that when the lentivirus is pseudotyped with F and HN it is efficient at entering lung cells and the gene it carries can be expressed for many months, even years in some situations. Another key feature that this pseudotyped virus displays is that it can be repeatedly administered, a property we have not seen previously with other viruses. This has an important advantage for treating chronic diseases, such as CF where the effects last for the life-time of the individual. The objectives of this application are i) to engineer the virus so it is suitable for use in patients; ii) to improve virus production methods so that it can be made in sufficient quantities to use as a therapy; and iii) to understand the potential for side-effects associated with administering the virus. The research project is 18 months long and at the end of it we hope to have selected a final version of the virus that we can take forward to test in patients. If we are successful in manufacturing the virus and selecting a suitable version to give to patients, we envisage that it could be delivered to the lungs of CF individuals using a device called a nebuliser, which generates a fine mist that can be breathed in. The increased efficiency of this virus along with the ability to have an effect that is long-lived effect means that this could form the basis of a new, more effective treatment for CF.</gtr:abstractText><gtr:technicalSummary>Cystic fibrosis (CF) is the most common lethal inherited disease of Caucasian populations, affecting ~80,000 individuals worldwide. In the UK, the current median age at death is ~25 years. Current treatments are focused on symptomatic relief and are associated with a huge treatment burden, and high individual NHS patient costs. No treatment is available that targets the genetic defect.

We have developed a novel, IP-protected, lentiviral gene transfer vector, specifically pseudotyped to enable efficient airway cell uptake. We hypothesise that CFTR gene transfer into the CF lung by this vector system will provide an effective treatment for CF lung disease.

The vector directs stable gene expression in lung models at levels thought to be within the therapeutic range. Uniquely, this vector system suffers no loss of efficacy upon repeated administration; with transgene expression remaining ~2 logs higher than current competing vector technologies.

Prior to final candidate selection key aspects of the vector system must be enhanced. Firstly, the current vector system is not fully compliant with pharmacopoeial regulations; however, straightforward sequence manipulation will rectify this issue. Secondly, the current vector purification methodology is difficult to scale. Simple method development, utilising steps previously applied in the field, will provide a scaleable GMP compatible production process. Thirdly, concerns driven by clinical findings from the use of early-generation retroviral vectors, requires an understanding of the effect of the vector transgene expression cassette upon theoretical insertion site-specific clonal expansion. Consequently, insertion site profiling is prudent prior to seeking regulatory approval for clinical studies. We outline a milestone-driven, 18 months translational research programme to bridge our current pre-clinical data package to regulatory toxicology studies and first-in-man trials.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from this research?
The ultimate objective of this research is to develop a treatment for the serious life threatening disease cystic fibrosis (CF). CF is the most common lethal inherited disease of Caucasian populations, International patient registries indicate that there are ~80,000 CF subjects in the EU, North America and Australia/New Zealand. Approximately 10% of this population live in the UK. In addition, some estimates suggest that an additional ~200K CF subjects are unidentified in emerging pharmaceutical markets. Typically, CF individuals suffer from repeated bacterial infections of the conducting airways leading to lung failure. Current treatments are focused on symptomatic relief and are associated with a huge treatment burden, requiring several hours of self-administered therapy daily. In the UK, the median age at death is ~25 years. NHS costs per patient range from &amp;pound;15 - &amp;pound;50K per year, with an annual direct healthcare cost of ~&amp;pound;200M. No treatment is available that targets the genetic defect; bridging this gap has been shown to be the highest priority of patients and carers.

Our solution to this problem is a novel, lentiviral gene transfer vector (termed F/HN-SIV), specifically engineered to enable efficient airway cell uptake. F/HN-SIV directs stable gene expression in cells relevant to CF lung disease for ~2 years following a single application. We hypothesise that gene transfer of a copy of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene into the CF lung by this repeatedly administrable vector will provide an effective treatment for CF lung disease.

The F/HN-SIV vector is the class leading solution to the problem of delivering nucleic acid-based therapeutics to the lung. As a platform for lung delivery additional therapeutic intervention options include: (1) the delivery of CFTR or other transgenes to treat acquired or inherited lung diseases - eg alpha 1-antitrypsin to treat emphysema/ chronic obstructive ponary disease (COPD), (2) the delivery of inhibitory molecules to treat viral infections or pre-existing lung disease - eg RNAi/miRNA class sequences to teat influenza/asthma, and (3) the delivery of transgenes to lung cells acting as a secreted protein factory to treat systemic disease - eg Factor VIII or IX to treat haemophilias.

How will end-users benefit from this research?
While modern CF treatment regimens have extended the life expectancy of a CF child, CF remains a lethal disease with no cure. Typically, CF patients require twice-daily regimens of physiotherapy and nebuliser treatments, supplemented with numerous orally delivered medications, imposing a high therapeutic burden (3-4 hours treatment/day is not unusual) on them and their carers. Successful gene therapy will provide benefits ranging from a reduction in (i) the conventional treatment burden, and (ii) time in hospital, manifesting through an increased life expectancy, to prevention of lung disease if treatment is started early after diagnosis. Our experience is that there is enthusiasm for gene therapy amongst CF individuals, but also a sense of realism. If successful CF gene therapy will have a dramatic effect on patient well-being, and the potential benefits to end users are large.

Following this 18 month project, we estimate it will take ~2.5 years to complete the required safety toxicology studies before a first-in-man clinical trial can be initiated. If successful, a CF treatment based on F/HN-SIV technology could be marketed within 10 years.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1280829</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>DNAVEC Corporation</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>DNAVEC and UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>97019158-F5B1-422C-9D1C-B1D332B4F496</gtr:id><gtr:impact>Publication number; WO2007049752
Publication number; WO2005001082
Publication number; WO0238786</gtr:impact><gtr:outcomeId>CWLaaBtZCwm-1</gtr:outcomeId><gtr:partnerContribution>DNAVEC: 
* Technology Transfer to the Consortium
University of Edinburgh and ICSTM. 
* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.
Imperial innovations: 
* IP Management</gtr:partnerContribution><gtr:piContribution>* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial Innovations</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DNAVEC and UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>075304FC-6BEF-475A-A369-6B71029AB0BE</gtr:id><gtr:impact>Publication number; WO2007049752
Publication number; WO2005001082
Publication number; WO0238786</gtr:impact><gtr:outcomeId>CWLaaBtZCwm-4</gtr:outcomeId><gtr:partnerContribution>DNAVEC: 
* Technology Transfer to the Consortium
University of Edinburgh and ICSTM. 
* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.
Imperial innovations: 
* IP Management</gtr:partnerContribution><gtr:piContribution>* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>DNAVEC and UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>6DBABE81-F734-4C54-9603-E531A1B109D0</gtr:id><gtr:impact>Publication number; WO2007049752
Publication number; WO2005001082
Publication number; WO0238786</gtr:impact><gtr:outcomeId>CWLaaBtZCwm-2</gtr:outcomeId><gtr:partnerContribution>DNAVEC: 
* Technology Transfer to the Consortium
University of Edinburgh and ICSTM. 
* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.
Imperial innovations: 
* IP Management</gtr:partnerContribution><gtr:piContribution>* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Genetics &amp; Molecular Medicine</gtr:department><gtr:description>DNAVEC and UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>C275828D-9484-4108-9767-8296197FC8C4</gtr:id><gtr:impact>Publication number; WO2007049752
Publication number; WO2005001082
Publication number; WO0238786</gtr:impact><gtr:outcomeId>CWLaaBtZCwm-3</gtr:outcomeId><gtr:partnerContribution>DNAVEC: 
* Technology Transfer to the Consortium
University of Edinburgh and ICSTM. 
* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.
Imperial innovations: 
* IP Management</gtr:partnerContribution><gtr:piContribution>* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DNAVEC and UK Cystic Fibrosis Gene Therapy Consortium</gtr:description><gtr:id>57A59740-ACCC-453C-B067-8BF2425FCB86</gtr:id><gtr:impact>Publication number; WO2007049752
Publication number; WO2005001082
Publication number; WO0238786</gtr:impact><gtr:outcomeId>CWLaaBtZCwm-5</gtr:outcomeId><gtr:partnerContribution>DNAVEC: 
* Technology Transfer to the Consortium
University of Edinburgh and ICSTM. 
* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.
Imperial innovations: 
* IP Management</gtr:partnerContribution><gtr:piContribution>* Vector improvements/modifications
* Assessment of genotoxicity and biodistribution
* Vector production and scale-up.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The Institute of Genetic Medicine Seminar - Lung Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CB18C5D5-5189-4741-8772-C0F22B783195</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56ceffca553724.99782587</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Navigating The Future Of Healthcare - Academy Of Medical Sciences - 2016/07/08</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FCCF7FE6-9425-4C13-A045-6666168AAD69</gtr:id><gtr:impact>Science education workshop. Encouraging career participation and development especially for women scientist.</gtr:impact><gtr:outcomeId>58befcc5a4b738.60387721</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://acmedsci.ac.uk/more/events/navigating-the-future-of-healthcare</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Stephen Hyde contributed to grant discussions for the Cystic Fibrosis Foundation</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98B288CC-90EF-45B2-85DA-CEA91F1A1D02</gtr:id><gtr:impact>Dr Stephen Hyde contributed to expect discussions for the Cystic Fibrosis Foundation to conduct grant reviews</gtr:impact><gtr:outcomeId>58c00d59bdc6a3.12070631</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>38th European Cystic Fibrosis Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9CB7DC83-C8CC-4153-92CF-4344C36D350F</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ced0835e68f9.60667764</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio London (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>77A788A2-6B99-4ADF-B8DE-D4622A3A709F</gtr:id><gtr:impact>BBC Radio London Breakfast Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c346b482b113.89043085</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pirbright Research Institute - Lung Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CFF4DAD-49D6-4044-B350-59A9A6925291</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cef1566c73c3.19219078</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC World Service - World Have Your Say - 2017/03/03</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>92CBEF87-CC47-49A7-B7F0-54228A4CF577</gtr:id><gtr:impact>BBC World Service Discussion Programme regarding gene therapy in general, specially the use of lentiviral vectors and the correction of sickle cell anaemia.</gtr:impact><gtr:outcomeId>58befde0811304.40667132</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/p04tv5n9</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford University Presentation 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>96A7EE39-FE24-4717-9E0B-95C15198EEFC</gtr:id><gtr:impact>Presentation of research activities with local (Oxford University) researchers to share knowledge and promote collaboraiton</gtr:impact><gtr:outcomeId>56ddbf0a578395.08910518</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>German Society for Gene Therapy (Vienna)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9E5BF9E0-BBE4-4E28-A2C9-56DEA36F0916</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ced00f720bc3.63695133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio2 Jeremy Vine Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EDA99704-F601-4103-8B72-3F0B00C5CE1C</gtr:id><gtr:impact>BBC Radio2 Jeremy Vine Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c3476ef0ef25.09935081</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alport Society Annual Meeting - CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>712756BE-5111-46D5-BBBF-D6F329B98E83</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefeadd59ff9.06156068</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BTS Winter Meeting (London)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1F639897-BD38-4375-9D0B-B7FDC070CFAF</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56cef0fbab7bd8.54413117</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science in Health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C91C14CB-6110-42F1-8576-142B0BA533A9</gtr:id><gtr:impact>Highlighting the awareness of CF and GT to the wider public


Stimulated enthusiasm around the Gene Therapy trial.</gtr:impact><gtr:outcomeId>5460af1ce19948.42557724</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alports Syndrome International Workshop (2015)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>61F9A1A2-862C-400B-ABC6-5F87791B2595</gtr:id><gtr:impact>Presentation to ~150 people attending international workshop on Alports syndrome. Individuals included patients, carers and scientific researchers. Introduced new therapeutic concepts. Wide ranging discussions followed.</gtr:impact><gtr:outcomeId>56c34b27b3c3d8.52911491</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Parents of Children with CF (RHSC Edinburgh)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0F934D46-B99A-4C0B-84B2-A8AEC2D2837E</gtr:id><gtr:impact>Chris Boyd and a member of his lab team gave presentations on the clinical trial work and ongoing research being undertaken by the UKCFGT Consortium. Approx 15 parents and carers of children with cystic fibrosis attended the talks and were able to informally ask questions regarding present and future studies that their children may be eligible to take part in.</gtr:impact><gtr:outcomeId>56cc6e92952f06.97779720</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSGCT Public Engagement Day Oxford 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>620F93D3-E137-4E2F-BEE3-620441188390</gtr:id><gtr:impact>One day of engagement (workshops and talks and discussions) which local schools, also open to general public</gtr:impact><gtr:outcomeId>56cf3faeefd7a4.83478081</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sixth Form Talk Oxford 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>238ABC5A-2FC9-415B-95AB-2A3C9F1A6A84</gtr:id><gtr:impact>Presentation of science research to sixth formers and GCSE students at local school, also discussed careers in science.</gtr:impact><gtr:outcomeId>56cf40273795c4.95089171</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Respiratory Society Annual Meeting - Update on CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>03A9FC05-94EE-4578-B2B0-4F02461FAA44</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefeff448228.19914971</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 5Live Breakfast Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C92D7B1D-1B42-41BD-98A2-20B1C73FD07E</gtr:id><gtr:impact>BBC Radio 5Live Breakfast show. Broadcast interview to discuss clinical trial results</gtr:impact><gtr:outcomeId>56c34717452b24.53624775</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CF Unite, Nottingham - CF Genetics and Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5EC2ED24-8B1E-4A6C-9920-28B1E899B5E3</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cef0ce161656.80320006</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Talk (Bradfield College 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C8BA14C0-2460-4097-B190-3D932C4EA2E1</gtr:id><gtr:impact>Science discussion evenning event at Bradfield College. Wide ranging audience from school children to CF care givers and relatives. Talk stimulated extensive discussion and questions.</gtr:impact><gtr:outcomeId>56c349aebc9bb2.85585112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to EIT Health Innovation Summit: Enhancement of lenitivral vector production through alteration of virus-cell interactions</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8F39DFEC-388F-46BF-8CF3-B1E7227228BB</gtr:id><gtr:impact>Presentation by student/new fellow (Dr JF Gelinas) to EIT Health Innovation Summit: Enhancement of lenitivral vector production through alteration of virus-cell interactions. Approx 350 participants from Research Institutions, Universities and Govt bodies attended the Summit. The presentation was on Lentiviral vector production and the enhancements made which is a project funded by EIT Health Innovations.</gtr:impact><gtr:outcomeId>58b800b690c9f2.96438323</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>065146E1-206F-431A-A4A9-358BEE80914A</gtr:id><gtr:impact>Communication of Science related topics to the wider public.

Widespread enthusiasm amongst participants.</gtr:impact><gtr:outcomeId>YQmnfBwvyLN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation Karolinska Institute 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C7B76C1-B8B6-4860-8A27-701437EBB4BE</gtr:id><gtr:impact>Dissemination of scientific findings in a general CF gene therapy context to range of practitioners</gtr:impact><gtr:outcomeId>56dedda5842311.82187066</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>German Mukoviscidose Gesellschaft Annual Meeting - Moving forward with CF Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9EFD4445-8BA8-4270-94FA-A6AFCE3C1859</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefe36417d13.40541699</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Stephen Hyde attended Cystic Fibrosis Foundation to conduct grant reviews</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7DD70F40-4F47-47DB-9CD6-C78C7F59FAF2</gtr:id><gtr:impact>Dr Stephen Hyde attended Cystic Fibrosis Foundation to conduct grant reviews</gtr:impact><gtr:outcomeId>58c00d077d1721.57669744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to University College (Wadham College Oxford) on Gene Therapy for Cystic Fibrosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>964B50C8-FF79-440E-A906-7B5FE3A16E7C</gtr:id><gtr:impact>Presentation to University College (Wadham College Oxford) on Gene Therapy for Cystic Fibrosis.
30 under graduate students attended a presentation on Gene Therapy for Cystic Fibrosis: Finally Turning the Hype into Clinical Progess. This sparked questions and discussion afterwards and gave students more awareness of Gene Therapy and how it can help sufferers of Cystic Fibrosis</gtr:impact><gtr:outcomeId>58b7fd430bac84.05635054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio 5Live Your Call Show (2016)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0CCB5770-CAC4-430F-AD9F-552612285A0E</gtr:id><gtr:impact>Was asked to act as scientific expert regarding cystic fibrosis during national radio phone in show.</gtr:impact><gtr:outcomeId>56ddbbe4bdb957.72138815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b0717346</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>3rd Annual CF Science Appreciation Dinner (2015)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>243FF68C-16B4-4973-8798-E0B63421A9E2</gtr:id><gtr:impact>3rd Annual CF Science Appreciation Dinner. 25 fund raisers, care givers and scientists involved with cystic fibrosis research. Networking and speaking event which sparked questions and discussions.</gtr:impact><gtr:outcomeId>56c348a8a3a780.54309789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECFS Diagnostic Network Working Group - CFTR gene therapy: What does the future hold</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>265B5FA4-7E77-4C01-B715-968FC5B8C667</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cf015dc44447.60321574</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Animal models Conference - Cystic fibrosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8E30A0F7-9C69-44C2-B175-82DFF743FB21</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cf003b6f2084.34211962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSGCT Public Engagement Day Oxford 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D50AB24F-8393-43DF-B76F-4ABEC998D850</gtr:id><gtr:impact>Local event at Oxford Natural History museum to debate gene therapy for a variety of diseases, attended by local school children</gtr:impact><gtr:outcomeId>56cf40aeafd8c1.67232209</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRT World - News Report - 2017/03/03</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0007A5A0-DB44-4D2D-8084-4C6CA172D8DE</gtr:id><gtr:impact>TV interview discussing gene therapy, lentiviral vectors and genetic disease</gtr:impact><gtr:outcomeId>58befe79e07154.60145976</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.trtworld.com</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual A-Level GCSE student Practical</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D7BF3631-E56A-4C8E-BA45-0EC1A8B7515C</gtr:id><gtr:impact>Annually 5-6 attend the workshop, often inspired to take up careers in Science and Medicine.

Increase in applications to Science and Medical Universities.</gtr:impact><gtr:outcomeId>Rt4u2VMdiqU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual North American CF Conference - British Society for Gene Therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>601F997D-75CF-4ACA-BE04-F979E1556858</gtr:id><gtr:impact>Highlight awareness of GT and CF to the wider public</gtr:impact><gtr:outcomeId>56cef006f41ce2.37500639</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual American Society for Gene and Cell Therapy - Selection of Regulator-compliant Optimal Lentiviral Vector Configurations for Progression into CF Clinical Trials</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50B6EB95-DB76-486B-BE29-2A8F59439D6D</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public

Stimulated enthusiasm aorund GT trial</gtr:impact><gtr:outcomeId>5464b27298f2f1.72797816</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC2 TV Victoria Derbyshire Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E1A00D3A-21A8-4ED0-9D75-72CEFF4BDDB0</gtr:id><gtr:impact>BBC2 TV Victoria Derbyshire Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c347e7a0cc03.32314265</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio Oxford Drivetime Show (2015)</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>013AB734-8FA7-4CDC-9821-06D8AFBB993F</gtr:id><gtr:impact>BBC Radio Oxford Drivetime Show. Broadcast interview to discuss clinical trial results.</gtr:impact><gtr:outcomeId>56c347b2dc49e5.61369308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Quintiles - Success and challenges in CF gene therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C62B4E3F-6BDF-43CD-801C-ED48F0AF035B</gtr:id><gtr:impact>Highlighted awareness of CF and GT to the wider public</gtr:impact><gtr:outcomeId>56cefde0a64145.68108073</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imperial College Fringe Event</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>10978059-D579-4DCC-BED3-36CEDFAEBBDA</gtr:id><gtr:impact>Communication of science to the public


Wide spread enthusiasm amongst participates.</gtr:impact><gtr:outcomeId>YqqvwCKKZG5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientific Talk Bradfield College 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DDDF94E8-7348-4DB3-A327-EB94BF3FC6E2</gtr:id><gtr:impact>Science discussion evening event
Extensive Q &amp;amp; A session</gtr:impact><gtr:outcomeId>56cf3b81bed0f8.75196215</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSM Cystic Fibrosis Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71263F25-C70C-49CD-9255-38D4264653B0</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ceee6c792693.33095432</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rare Disease Awareness Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>73974B5B-69D7-46FC-AF72-909F2E6692E9</gtr:id><gtr:impact>Highlighting the awareness of CF and GT to the wider public.

Stimulated enthusiasm for Science and Medical topics to the wider public.</gtr:impact><gtr:outcomeId>UxQUHPbd3Ck</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cystic Fibrosis Trust: Lungs for the Life Conference (Manchester)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA22C7AD-A28E-47E0-B991-DA3DDCC9CACB</gtr:id><gtr:impact>Extensive interest in world 1st non-viral trial of Gene Therapy aimed at Clinical improvement. Discussions underway with Pharma for follow on study.</gtr:impact><gtr:outcomeId>56ceee387d0ec8.20304552</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>96009</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An Interim application to fund UK Gene Therapy Consortium</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:fundingRef>GT013</gtr:fundingRef><gtr:id>FD08DF07-5381-4394-959E-158713E81F50</gtr:id><gtr:outcomeId>ZFgdWdHA3Qx</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>RDM Pump Priming Award</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>5610E9B6-E920-4944-AC1B-C3B1FCEA5213</gtr:id><gtr:outcomeId>54639001d76555.09553958</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49942</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Council Confidence in Concept Fund</gtr:department><gtr:description>Confidence in Concept</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>F0E9687D-CAE0-4751-9C0B-373C071E8293</gtr:id><gtr:outcomeId>546390d21ceb67.34294031</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52362</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Airway epithelium as a factory for production of blood clotting factors</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:fundingRef>P47167</gtr:fundingRef><gtr:id>ED63E72D-A66E-43EE-A2EF-430E1E5E3F8B</gtr:id><gtr:outcomeId>fxKfgcZLJzW</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Hungary, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EIT Health Innovations</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>European Institute of Innovation and Technology (EIT)</gtr:fundingOrg><gtr:id>67492FB1-589B-4655-800E-74CBC2096AD1</gtr:id><gtr:outcomeId>58b7f94279c131.86325237</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>Liechtenstein, Principality of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GT consortia Core Funding</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Medicor Foundation</gtr:fundingOrg><gtr:id>80FED2EC-22BB-4079-BDD4-04B8396814F8</gtr:id><gtr:outcomeId>56d8741bc0c267.44330068</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>170213</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An Interim application to fund the UK Gene Therapy Consortium</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:fundingRef>GT012</gtr:fundingRef><gtr:id>70620ED7-250A-4D06-BC65-2310B937A30C</gtr:id><gtr:outcomeId>fjdE8M78eyv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>142693</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An application to fund the UK CF Gene Therapy Consortium core costs</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:id>EBF137CE-AC76-41E9-9CD1-741EBC608E57</gtr:id><gtr:outcomeId>5457a1c3e58f83.44609070</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>41778</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>An interim application to fund the UK Gene Therapy Consortium</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Cystic Fibrosis Trust</gtr:fundingOrg><gtr:fundingRef>GT014</gtr:fundingRef><gtr:id>8125D1C3-283B-40BA-BD56-AFDEFB25B6AF</gtr:id><gtr:outcomeId>XK7W1W2iz3K</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Oxford University Innovation</gtr:department><gtr:description>University Challenge Seed Fund</gtr:description><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:fundingRef>Enhancement of Lentiviral Production</gtr:fundingRef><gtr:id>A6906BDF-5D5B-44E8-BBBF-243BD95F7F22</gtr:id><gtr:outcomeId>58b7fa9c115883.01237004</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR RBRU Pump Priming</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Royal Brompton &amp; Harefield NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>P45585</gtr:fundingRef><gtr:id>CDE4FBC0-7D59-4DD4-BFDD-9F0C4C374C26</gtr:id><gtr:outcomeId>pmj8V2kmWGu</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This patent is Background IP to the MRC project and is owned by DNAVEC Corp (now ID Pharma Co.), Japan. The patent describes the candidate F/HN SIV lentiviral vectors developed as a therapy for cystic fibrosis, and other indications, including manufacturing methods.</gtr:description><gtr:grantRef>MR/J014699/1</gtr:grantRef><gtr:id>25CE71AF-7248-45C3-9E72-83025D23B32C</gtr:id><gtr:impact>This patent is owned jointly between DNAVEC Corp (now ID Pharma Co.). and Imperial Innovations Ltd, and forms part of the Core Technology and Background IP. A research and sub-licensable commercial use licence under this patent has been granted to Imperial College, Universities of Oxford and Edinburgh, and Imperial Innovations Ltd. 
The patent is published, due to enter national/regional phase in November 2016.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56b4a4462675f9.03247311</gtr:outcomeId><gtr:patentId>WO2015177501</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Lentiviral Vectors</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent is Background IP to the MRC project and is owned by DNAVEC Corp (now ID Pharma Co.), Japan. It describes the use of lentiviral vectors pseudotyped with viral spike proteins as a means to achieve gene transfer into the airway epithelial cells.</gtr:description><gtr:grantRef>MR/J014699/1</gtr:grantRef><gtr:id>F21A6593-F399-4BA8-8219-6A6B51C353E5</gtr:id><gtr:impact>This patent is owned by DNAVEC Corp (now ID Pharma Co.). and forms part of the Core Technology and Background IP. A research and sub-licensable commercial use licence under this patent has been granted to Imperial College, Universities of Oxford and Edinburgh, and Imperial Innovations Ltd. 
Patents are also pending in US, Canada and Japan.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56b4a2794a30c5.00866358</gtr:outcomeId><gtr:patentId>EP1950307</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Gene transfer into airway epithelial stem cell</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent is owned by DNAVEC Corp (now ID Pharma Co.) and is Background IP to the MRC project. The patent relates to Recombinant Sendai virus vector for introducing exogenous genes to airway epithelia and claims efficiency of airway epithelial cell entry via Sendai F and HN proteins.</gtr:description><gtr:grantRef>MR/J014699/1</gtr:grantRef><gtr:id>53E7C744-F622-4E48-AF61-EBDA1A54C757</gtr:id><gtr:impact>This patent is owned by DNAVEC Corp. (now ID Pharma Co.) and forms part of the Core Technology and Background IP. A research and sub-licensable commercial use right under this patent has been granted to Imperial College, Universities of Oxford and Edinburgh, and Imperial Innovations Ltd. 
The patent has also been granted in US (US7314614), Canada ( CA2389743) and Japan ( JP4838962).</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>o7Md4z5drHd</gtr:outcomeId><gtr:patentId>CN1252274</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Recombinant sendai virus vector</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent is Background IP to the MRC project and is owned by DNAVEC Corp (now ID Pharma Co.), Japan. It relates to pseudotyped retroviral vectors which can be used as gene transfer agents, with specific claims covering retroviral vectors pseudotyped with Sendai virus F and HN proteins.</gtr:description><gtr:grantRef>MR/J014699/1</gtr:grantRef><gtr:id>1F4D320D-7672-48A7-9769-0542CF931CFF</gtr:id><gtr:impact>This patent is owned by DNAVEC Corp (now ID Pharma Co.). and forms part of the Core Technology and Background IP. A research and sub-licensable commercial use licence under this patent has been granted to Imperial College, Universities of Oxford and Edinburgh, and Imperial Innovations Ltd. 
The patent has also been granted in Canada ( CA2413995), Europe (EP1291419), US (US7510706), Japan ( JP4700888) and Korea (KR100807016).</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>XZfENBvX7cV</gtr:outcomeId><gtr:patentId>CN100531802</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Pseudotyped retroviral vectors</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of strategy implementation board of the cystic fibrosis trust.</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D860D78D-0396-4E59-A4DC-78A1882C1D25</gtr:id><gtr:outcomeId>ThqrUieiAnb</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>methods to manufacture cGMP Lentiviral vectors</gtr:description><gtr:id>4E357F57-AD5F-443F-BC3F-CA3A81639CE9</gtr:id><gtr:impact>Multiple lots of Lentiviral vectors manufactured for non clinical toxicological studies.</gtr:impact><gtr:outcomeId>TuTaWU7j1ph</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>cGMP-compliant Lentiviral production methods</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Plasmids designed to generate recombinant Lentiviral vectors</gtr:description><gtr:id>C9E46EA1-1B91-4CC5-B84C-7C9834B926DF</gtr:id><gtr:impact>N/a at this stage</gtr:impact><gtr:outcomeId>DqqbgNiM6iv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Novel integrating &amp; non-integrating Lentiviral vectors</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5FFF35BB-6703-4E80-9733-C3D80CE79D54</gtr:id><gtr:title>Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42f5800291845f7353b10c7923c91fd6"><gtr:id>42f5800291845f7353b10c7923c91fd6</gtr:id><gtr:otherNames>Pytel K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a2f1a36f70d1.90264879</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEF2E36B-44F7-463F-8FED-B1FD8ADC1264</gtr:id><gtr:title>Pediatric Pulmonary</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e455bfad4540cd2c1a444d4a4fc410e"><gtr:id>0e455bfad4540cd2c1a444d4a4fc410e</gtr:id><gtr:otherNames>Davidson H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54636c6c32e778.25715234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEB63EC0-2D5D-45CA-A2E4-5B703246D424</gtr:id><gtr:title>Delivery of genes into the CF airway.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f76c57d4bc46e506eb309ab52020dbe"><gtr:id>4f76c57d4bc46e506eb309ab52020dbe</gtr:id><gtr:otherNames>Gill DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>546382af5adec6.92569935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>784EB053-675F-4747-8CBD-464A3C459901</gtr:id><gtr:title>Development of F/HN pseudotyped Lentivirus for airway gene transfer</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81c4c656d09928c4915d536ca5d94fcc"><gtr:id>81c4c656d09928c4915d536ca5d94fcc</gtr:id><gtr:otherNames>Gill, DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54637192bdd369.50619605</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E74591D-006D-4D9C-BCB7-5D78810E0091</gtr:id><gtr:title>LARGE-SCALE PRODUCTION OF LENTIVIRAL VECTORS FOR CF LUNG GENE THERAPY</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6538c149be48dedb41d6208c3dfb7746"><gtr:id>6538c149be48dedb41d6208c3dfb7746</gtr:id><gtr:otherNames>Davies, LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54636f10e4ea12.90583411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70EBF6DE-B7E8-4780-A46A-921584F5040C</gtr:id><gtr:title>Moving towards assessment of lentiviral vector in clinical trial</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b1bf170f33fee45fb46e46d5fa7eb54"><gtr:id>9b1bf170f33fee45fb46e46d5fa7eb54</gtr:id><gtr:otherNames>Griesenbach, U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546380fb61d1e9.41197909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A5F7456-A449-4C9A-BC07-C37B554A1F07</gtr:id><gtr:title>534. Preparation for a First-in-Man Lentivirus Trial in Cystic Fibrosis Patients</gtr:title><gtr:parentPublicationTitle>Molecular Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a2ee8ab8d5a8.86247683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF028A20-6E09-4B38-A79F-DAF8BA44443D</gtr:id><gtr:title>Enhanced lentiviral production through rational design of mammalian host cells</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67eac823f96ddafb8e3e630340142de9"><gtr:id>67eac823f96ddafb8e3e630340142de9</gtr:id><gtr:otherNames>Hyde SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b7eaa1efcfc6.94798566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24D22C52-3B23-410C-877F-28073D7C536D</gtr:id><gtr:title>Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>546489b659f154.75801297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13BC9064-02EA-402A-8CED-CA5941538827</gtr:id><gtr:title>704. Enhanced Lentiviral Production Through Rational Design of Mammalian Host Cells</gtr:title><gtr:parentPublicationTitle>Molecular Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/891de191626d04fe90cb84d2c5d4c3ad"><gtr:id>891de191626d04fe90cb84d2c5d4c3ad</gtr:id><gtr:otherNames>Gelinas J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58a2f251a8f610.43278159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3060E747-69CB-44AA-849D-C553D57B7C8A</gtr:id><gtr:title>Moving forward: cystic fibrosis gene therapy.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a009e137431ad6368363564a4ceb3ebc"><gtr:id>a009e137431ad6368363564a4ceb3ebc</gtr:id><gtr:otherNames>Griesenbach U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56cde4b079c663.89713165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1358475-1D11-435B-9F1A-0A20D4FE46D0</gtr:id><gtr:title>Genetic medicines for CF: Hype versus reality.</gtr:title><gtr:parentPublicationTitle>Pediatric pulmonology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1099-0496</gtr:issn><gtr:outcomeId>58a2e7281bd521.84747006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE5D4C2A-41C6-4532-BDDC-551C51496D89</gtr:id><gtr:title>Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/858923b6ea0cd0e24d5bf7ad5151d91d"><gtr:id>858923b6ea0cd0e24d5bf7ad5151d91d</gtr:id><gtr:otherNames>Leoni G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn><gtr:outcomeId>56cee59a6d1a23.64730664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEAD415D-F434-486A-AD56-B73BE45A508E</gtr:id><gtr:title>Special focus issue on the annual meeting of the British Society for Gene and Cell Therapy.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a56ab8bae8e53f00ab8cbd3baf06f39"><gtr:id>0a56ab8bae8e53f00ab8cbd3baf06f39</gtr:id><gtr:otherNames>Nicklin SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>56d422890c53f5.47757187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D83F7DC-67C4-4C9C-BC7E-B07AE02C4A5D</gtr:id><gtr:title>Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22f4b0c676241659342f5bf9f5c2ce79"><gtr:id>22f4b0c676241659342f5bf9f5c2ce79</gtr:id><gtr:otherNames>Alton EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>58a2e75613cd99.29370245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51A6BECC-9C40-452E-93AC-B31AAC8E06EB</gtr:id><gtr:title>Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/495ae4caaca3f8e23d11359cf2683c00"><gtr:id>495ae4caaca3f8e23d11359cf2683c00</gtr:id><gtr:otherNames>Pringle, IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546373d3390166.31902142</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J014699/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>